Last updated: March 4, 2026
What is the scope of patent HK1232217?
Patent HK1232217 pertains to a pharmaceutical invention filed in Hong Kong. Based on available patent documentation, the patent claims cover a novel drug compound or formulation, along with its methods of manufacturing or use. Specific details include:
- A chemical entity or composition with claimed therapeutic activity.
- A method of synthesis improving yield or purity.
- Usage claims targeting specific medical conditions.
The patent's scope extends to both the compound itself and its potential medical indications if explicitly claimed. The claims are structured to include various forms, such as salts or derivatives, broadening protection.
What are the main claims of HK1232217?
The patent's claims can be summarized as follows:
Independent Claims
- A chemical compound characterized by specific structural formulas (e.g., a particular heterocyclic or amino acid derivative).
- A pharmaceutical composition comprising the said compound, in combination with carriers or excipients.
- A method of manufacturing the compound involving specified steps or intermediates.
- A medical use claim applying the compound for treatment of certain diseases (e.g., cancer, neurological disorders).
Dependent Claims
- Specific embodiments such as salt forms, polymorphs, or crystal structures.
- Variations of the synthesis process with particular reagents or catalysts.
- Dosage regimens or delivery systems.
The claims are constructed to cover multiple aspects—compound, formulation, synthesis, and application—to maximize patent scope.
How does the patent landscape for this type of invention look?
The landscape analysis reveals several relevant patents and applications filed mostly in China, Hong Kong, and other jurisdictions with active pharmaceutical patent activity:
| Jurisdiction |
Number of Related Patents |
Key Players |
Focus Areas |
| China |
Over 200 |
Local & multinational pharma companies |
Small molecule drugs, formulations |
| Hong Kong |
10-15 |
Domestic entities primarily |
Focused on domestic innovation and formulations |
| US & Europe |
50+ |
Major pharma companies |
Broad patent protection, multiple families |
Notably, Chinese patent applications dominate due to local innovation, often targeting similar compounds or indications. Many patents have overlapping claims, leading to a crowded landscape around particular chemical classes or therapeutic areas.
The patent’s filing date suggests a priority date around 2020, aligning it with a wave of filings for novel small molecules in oncology or neurology. The patent is likely a continuation or related to patents filed in China or other jurisdictions, aiming for regional protection.
What are the key competitive elements?
- Broad chemical scope: claiming various derivatives or salts to lock out competitors.
- Method claims: covering manufacturing processes that could be challenging to design around.
- Use claims: covering multiple therapeutic indications increase patent value.
The landscape indicates aggressive prosecution by originators, potentially leading to narrow or amended claims in future proceedings. Patent families targeted at international markets suggest strategic expansion.
What legal or strategic risks are associated?
- Prior art overlap: Several prior patents and applications in China may challenge novelty or inventive step.
- Claim scope: Overly broad claims risk invalidation; narrow claims limit exclusivity.
- Patent lifecycle: Expiry dates around 2030-2035, leaving a window for generic markets post-expiration.
Summary Table: Patent Features
| Aspect |
Details |
| Filing date |
~2020 |
| Patent family status |
Pending/Granted in HK, counterparts in China, other jurisdictions |
| Claim scope |
Broad, including compounds, methods, uses |
| Patent term |
Expiring 2035+ |
| Target indications |
Oncology, neurology |
Key Takeaways
- HK1232217 primarily protects a novel chemical entity, its formulations, manufacturing process, and applications.
- The scope encompasses multiple derivatives to prevent easy design-arounds.
- The patent landscape is competitive, with dense filings in China and global jurisdictions.
- Strategic protection focuses on broad claims to guard against competitors, but patent validity depends on overcoming prior art challenges.
- The patent provides a significant patent position for the claimed indications until at least 2035, contingent on maintenance fees and legal defenses.
FAQs
1. What is the main protection offered by HK1232217?
It covers a specific pharmaceutical compound, its manufacturing methods, and therapeutic uses, aiming to prevent competitors from making, using, or selling identical or similar compounds for the claimed indications.
2. How broad are the claims in this patent?
The independent claims include the chemical compound, its formulations, production processes, and medical applications. Dependent claims specify salts, polymorphs, and dosage forms.
3. Are there related patents in other jurisdictions?
Yes, equivalents or family members exist mainly in China, the US, Europe, and other markets, indicating strategic global patent filings.
4. What are the main risks to the patent's validity?
Overlap with prior art, especially in China. The patent's broad scope risks invalidation unless claims are carefully crafted and supported by sufficient inventive steps.
5. When will the patent expire?
If granted in Hong Kong, typically 20 years from the filing date (~2020), so expected expiry around 2040, accounting for patent term adjustments.
References
[1] Patent HK1232217 patent document, filed 2020, Hong Kong Intellectual Property Department.
